Investigational drug · Phase 2
NVG-2089
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Immune Thrombocytopenia (ITP).
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "NVG-2089"
First trial start
2025
Sep 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NVG-2089", any sponsor or status.
Conditions studied
As listed on its trial records.
- Immune Thrombocytopenia (ITP)
Approved drugs for the same conditions: Immune thrombocytopenia · Hematology and blood cancers · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "NVG-2089" as an intervention, largest first.
- Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune ThrombocytopeniaRecruiting
Nuvig Therapeutics, Inc.Industry
NCT07095127 · 30 participants (planned) · Start Sep 30, 2025 · Primary completion Jun 30, 2027
Drug: NVG-2089 · For: Immune Thrombocytopenia (ITP)
Sites: Washington D.C., District of Columbia; Boston, Massachusetts; Greenville, North Carolina
Nuvig Therapeutics, Inc.Industry
NCT07027111 · 14 participants · Start Apr 25, 2025 · Primary completion Oct 1, 2026
Drug: NVG-2089 · For: Chronic Inflammatory Demyelinating Polyneuropathy
Sites: Denton, Texas
Newest research
PubMed records naming it or its code names, newest first.
- A recombinant IgG1 Fc-domain protein ameliorates inflammatory demyelinating peripheral neuropathy.
Otlu HG, Gao T, Coffey GP, et al. · Front Immunol 2026
Also in development for Immune Thrombocytopenia (ITP)
- BirelentinibDZD8586Phase 37 trials
Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)
- CM336group, QiShen YiQi Dripping Pills 3 bagsPhase 37 trials
Keymed Biosciences Co.Ltd · Multiple Myeloma (MM), Primary Light-Chain Amyloidosis, Primary Immune Thrombocytopenia
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- BudoprutugTNT119Phase 23 trials
Climb Bio, Inc. · Primary Membranous Nephropathy, Systemic Lupus Erthematosus, Immune Thrombocytopenia (ITP)
- ESG206ESG206-2Phase 23 trials
Shanghai Escugen Biotechnology Co., Ltd · Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.